MaxCyte, Inc. Director/PDMR Shareholding (1438N)
October 21 2016 - 2:43AM
UK Regulatory
TIDMMXCT
RNS Number : 1438N
MaxCyte, Inc.
21 October 2016
MaxCyte, Inc.
("MaxCyte" or the "Company")
Driector/PDMR Sharedealing
Maryland, USA - 21 October 2016: MaxCyte (LSE: MXCT), the
revenue-generating developer of next generation cell-based
medicines, products and services, announces that it was notified on
20 October 2016 of the following transactions:
-- On 19 October 2016, John Johnston, a Non-Executive Director
of the Company, purchased 37,500 ordinary shares of 0.1 pence each
in the Company ("Ordinary Shares") at a price of 96 pence per
share; and
-- On 20 October 2016, Mr Johnston, purchased 37,500 Ordinary
Shares at a price of 98 pence per share, the ("Transactions").
Following the Transactions, Mr Johnston's total beneficial
interest in the Company is 75,000 Ordinary Shares, representing
approximately 0.17 per cent. of the current issued share
capital.
The notification below, made in accordance with the requirements
of the EU Market Abuse Regulation, provides further detail.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them.
1 Details of the person discharging managerial
responsibilities/person closely associated
---- ---------------------------------------------------------------
a) Name John Johnston
---- ------------------------- ------------------------------------
2 Reason for the notification
---- ---------------------------------------------------------------
a) Position/status Non-Executive Director
---- ------------------------- ------------------------------------
b) Initial Initial Notification
notification
/Amendment
---- ------------------------- ------------------------------------
3 Details of the issuer, emission allowance
market participant, auction platform, auctioneer
or auction monitor
---- ---------------------------------------------------------------
a) Name MaxCyte, Inc.
---- ------------------------- ------------------------------------
b) Legal Entity N/A
Identifier
---- ------------------------- ------------------------------------
4 Details of the transaction(s): section to
be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each
date; and (iv) each place where transactions
have been conducted
---- ---------------------------------------------------------------
a) Description Ordinary shares of 0.1 pence each
of the
financial
instrument, MXCT / US57777K1060
type of
instrument
Identification
code
---- ------------------------- ------------------------------------
b) Nature Purchase of shares
of the
transaction
---- ------------------------- ------------------------------------
c) Currency GBP
---- ------------------------- ------------------------------------
d) Price(s) Price(s) Volume(s)
and volume(s)
---- ------------------------- ----------------- -----------------
0.98 37500
------------------------------ ----------------- -----------------
0.96 37500
----------------- -----------------
e) Aggregated
information
- Aggregated
volume
- Price 75000
- Aggregated 0.97
total
GBP72,750
------------------------------ ------------------------------------
f) Date of 19/10/16
the transaction
20/10/16
------------------------------ ------------------------------------
g) Place of London Stock Exchange, AIM
the transaction
---- ------------------------- ------------------------------------
- ENDS -
For further information please contact:
MaxCyte +1 301 944 1660
Doug Doerfler, Chief Executive
Officer
Ron Holtz, Chief Financial
Officer
Nominated Adviser and Broker
Panmure Gordon
Freddy Crossley (Corporate
Finance)
Fabien Holler
Duncan Monteith
Tom Salvesen (Corporate Broking) +44 (0) 20 7886 2500
Financial PR Advisor +44 (0)203 709 5700
Consilium Strategic Communications maxcyte@consilium-comms.com
Mary-Jane Elliott
Chris Welsh
Lindsey Neville
About MaxCyte
MaxCyte is an established and revenue generating US-based
developer and supplier of cell engineering products and services to
biopharmaceutical firms engaged in cell therapy, drug discovery and
development, biomanufacturing, gene editing and immuno-oncology
markets, which independent market analyses estimate to be, in
aggregate, in excess of $35 billion in 2015. The Company's patented
flow electroporation technology enables its products to deliver
fast, reliable and scalable cell engineering to drive the research
and clinical development of a new generation of medicines.
MaxCyte's high performance platform allows transfection with any
molecule or multiple molecules and is compatible with nearly all
cell types, including hard-to-transfect human primary cells. It
also provides a high degree of consistency and minimal cell
disturbance, thereby facilitating rapid, large scale, clinical and
commercial grade cell engineering in a non-viral system and with
low toxicity concerns. The Company's cell engineering technology
platform is CE-marked and FDA-accredited, providing MaxCyte's
customers and partners with an established regulatory path.
Using the unique capabilities of its technology, MaxCyte is
developing CARMA, its proprietary platform in immuno-oncology, to
deliver a validated non-viral approach to CAR therapies across a
broad range of cancer indications, including solid tumors where
existing CAR-T approaches face significant challenges.
For more information visit http://www.maxcyte.com/
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHEAKEFALAKFEF
(END) Dow Jones Newswires
October 21, 2016 02:43 ET (06:43 GMT)
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Apr 2024 to May 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
From May 2023 to May 2024